What is the clinical evidence from this study?

Study design: Cohort. Population: Adolescent and young adult (AYA) lymphoma (n=825). Intervention: Cardiovascular disease diagnosis vs. No cardiovascular disease diagnosis. Primary outcome: Survival (HR 7.11, 95% CI 4.03-12.5).

What question did this study set out to answer?

The aim is to evaluate survival rates after a cardiovascular disease diagnosis in adolescents and young adults who survived lymphoma.

May 16, 2026

Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Key Result

The development of cardiovascular disease in survivors of adolescent and young adult lymphoma was highly associated with inferior survival (HR 7.11; 95% CI 4.03-12.5).

Key Points

The aim is to evaluate survival rates after a cardiovascular disease diagnosis in adolescents and young adults who survived lymphoma.
Collected demographics and treatment variables in a diverse population of 825 AYA lymphoma survivors.
Analyzed CVD diagnoses occurring at least 3 months after lymphoma diagnosis with median follow-up of 9.8 years.
Used Cox models to assess the relationship between CVD diagnosis and survival outcomes.
23.6% of participants had a cardiovascular disease diagnosis during follow-up.
CVD diagnosis was associated with significantly inferior survival (HR: 7.11, 95% CI: [4.03–12.5]).
The adverse survival impact was greater among Black and Hispanic patients, NHL survivors, and those with a healthy baseline BMI.

Study Design

Type

Cohort (n=825)

Structured PICO

Does the development of cardiovascular disease reduce survival in survivors of adolescent and young adult lymphoma?

Population

825 survivors of adolescent and young adult (AYA) lymphoma (58.5% White, 26.9% Hispanic, 14.5% Black)

Intervention

Diagnosis of cardiovascular disease (CVD) occurring at least 3 months after lymphoma diagnosis

Comparator

No cardiovascular disease diagnosis

Outcome

Survival (mortality)hard clinical

The development of cardiovascular disease in survivors of adolescent and young adult lymphoma is associated with a more than 7-fold increased risk of mortality, highlighting the critical need for cardiovascular surveillance in this population.

Main Result

Effect estimate: HR 7.11 (95% CI 4.03-12.5)

Abstract

ABSTRACT Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma. Therefore, in this study we evaluated survival after a diagnosis of CVD and investigated differences in the CVD‐survival relationship. Demographics, treatment variables, and CVD diagnoses occurring at least 3 months after their lymphoma diagnosis were collected in a diverse population of AYA lymphoma survivors ( N = 825; race/ethnicity: 58.5% White, 26.9% Hispanic, 14.5% Black). Nearly 25% (23.6%; N = 195) had a CVD diagnosis during the median follow‐up time of 9.8 years with the median age at CVD diagnosis being 33.0 years. In Cox models with CVD as a time‐varying covariate, the development of a CVD was highly associated with inferior survival (HR: 7.11, 95% CI: 4.03–12.5). This adverse CVD‐survival relationship was consistently observed among patient subpopulations; however, the magnitudes of the adverse effect of CVD on survival were most pronounced (HR > 7) among Black and Hispanic patients, NHL survivors, and those with a healthy baseline BMI. Together these findings underscore the need for cardiovascular health surveillance among survivors of AYA lymphoma to potentially mitigate this adverse effect of CVD on survival in this at‐risk population.

Bookmark